Rejection therapies

One hundred thirty-eight primary liver allograft recipients received cyclosporine and prednisolone immunosuppression with azathioprine added during the induction phase. All rejections were biopsy-confirmed clinical rejections. Acute rejection was seen in 58.7% of the patients. The treatment of acute rejection was successful in 88.9% of treated patients. Rejection-related death was seen in 4.3%, and retransplantation was performed for acute or chronic rejection in 2.2% of the patients. The risk for dying increased with the number of rejection treatments.